Alcoolizzazione percutanea dell'epatocarcinoma: Risultati a lungo termine

Translated title of the contribution: Percutaneous ethanol injection therapy for hepatocellular carcinoma: Long-term results

Riccardo Lencioni, Alessandro Paolicchi, Carlo Bartolozzi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We investigated the long-term outcome of percutaneous ethanol injection (PEI) in the treatment of hepatocellular carcinoma (HCC). A series of 184 HCC patients received PEI as the sole anticancer treatment over an 8-year period, December, 1987, to December, 1995. Ninety-four patients had a single tumor ≤ 3 cm, 50 patients had a single lesion of 3.1-5 cm, and 40 patients had multiple nodules (up to four) ≤ 3 cm each. All patients had liver cirrhosis, classified as Child-Pugh class A in 127 cases and as Child-Pugh class B in 57 cases. The treatment schedule included, for each lesion, 6-14 therapeutic sessions performed once or twice weekly. The total amount of alcohol administered ranged 10 to 110 ml (mean: 36 ml). All patients were followed after therapy with clinical examinations, laboratory tests, and imaging studies performed at regular time intervals. The follow-up period ranged 2 to 94 months (mean: 23.6 months). Overall survival rates by the Kaplan-Meier method were 67% at 3 years, 41% at 5 years, and 19% at 7 years. The survival rates of patients with single lesion ≤3 cm (78% at 3 years, 54% at 5 years, and 28% at 7 years, respectively) were significantly higher (p <.01) than those of the patients with a single lesion of 3.1-5 cm (61% at 3 years, 32% at 5 years, and 16% at 7 years) or multiple lesions (51% at 3 years, 21% at 5 years, and 0% at 7 years). The survival of Child-Pugh A patients (79% at 3 years, 53% at 5 years, and 32% at 7 years) was significantly longer (p <.01) than that of Child-Pugh B patients (50% at 3 years, 28% at 5 years, and 8% at 7 years). A selected group of 70 patients with Child-Pugh A cirrhosis and a single lesion ≤ 3 cm had a 3-, 5-, and 7-year survival of 89%, 63% and 42%, respectively. During the follow-up, new lesions appeared in 93 patients. The recurrence rates by the Kaplan-Meier method were 15% at 1 year, 34% at 2 years, 51% at 3 years, 67% at 4 years, 78% at 5 years, 88% at 6 years, and 94% at 7 years. The analysis of the survival curves of the treated patients confirms the effectiveness of PEI in the treatment of HCC. This therapeutic approach is particularly indicated for patients with a single lesion 3 cm or less in greatest diameter, as in these cases the long-term results of PEI are comparable to those reported in the best surgical series published in the literature.

Original languageItalian
Pages (from-to)8-13
Number of pages6
JournalRadiologia Medica
Volume94
Issue number1-2
StatePublished - Jul 1997
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Ethanol
Injections
Therapeutics
Survival Rate
Survival
Survival Analysis
Liver Cirrhosis
Appointments and Schedules
Fibrosis
Alcohols
Recurrence

Keywords

  • HCC, interventional radiology
  • HCC, therapy
  • Liver neoplasms, therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Lencioni, R., Paolicchi, A., & Bartolozzi, C. (1997). Alcoolizzazione percutanea dell'epatocarcinoma: Risultati a lungo termine. Radiologia Medica, 94(1-2), 8-13.

Alcoolizzazione percutanea dell'epatocarcinoma : Risultati a lungo termine. / Lencioni, Riccardo; Paolicchi, Alessandro; Bartolozzi, Carlo.

In: Radiologia Medica, Vol. 94, No. 1-2, 07.1997, p. 8-13.

Research output: Contribution to journalArticle

Lencioni, R, Paolicchi, A & Bartolozzi, C 1997, 'Alcoolizzazione percutanea dell'epatocarcinoma: Risultati a lungo termine', Radiologia Medica, vol. 94, no. 1-2, pp. 8-13.
Lencioni R, Paolicchi A, Bartolozzi C. Alcoolizzazione percutanea dell'epatocarcinoma: Risultati a lungo termine. Radiologia Medica. 1997 Jul;94(1-2):8-13.
Lencioni, Riccardo ; Paolicchi, Alessandro ; Bartolozzi, Carlo. / Alcoolizzazione percutanea dell'epatocarcinoma : Risultati a lungo termine. In: Radiologia Medica. 1997 ; Vol. 94, No. 1-2. pp. 8-13.
@article{d02ab5e8f22b4239be5b521d590f416a,
title = "Alcoolizzazione percutanea dell'epatocarcinoma: Risultati a lungo termine",
abstract = "We investigated the long-term outcome of percutaneous ethanol injection (PEI) in the treatment of hepatocellular carcinoma (HCC). A series of 184 HCC patients received PEI as the sole anticancer treatment over an 8-year period, December, 1987, to December, 1995. Ninety-four patients had a single tumor ≤ 3 cm, 50 patients had a single lesion of 3.1-5 cm, and 40 patients had multiple nodules (up to four) ≤ 3 cm each. All patients had liver cirrhosis, classified as Child-Pugh class A in 127 cases and as Child-Pugh class B in 57 cases. The treatment schedule included, for each lesion, 6-14 therapeutic sessions performed once or twice weekly. The total amount of alcohol administered ranged 10 to 110 ml (mean: 36 ml). All patients were followed after therapy with clinical examinations, laboratory tests, and imaging studies performed at regular time intervals. The follow-up period ranged 2 to 94 months (mean: 23.6 months). Overall survival rates by the Kaplan-Meier method were 67{\%} at 3 years, 41{\%} at 5 years, and 19{\%} at 7 years. The survival rates of patients with single lesion ≤3 cm (78{\%} at 3 years, 54{\%} at 5 years, and 28{\%} at 7 years, respectively) were significantly higher (p <.01) than those of the patients with a single lesion of 3.1-5 cm (61{\%} at 3 years, 32{\%} at 5 years, and 16{\%} at 7 years) or multiple lesions (51{\%} at 3 years, 21{\%} at 5 years, and 0{\%} at 7 years). The survival of Child-Pugh A patients (79{\%} at 3 years, 53{\%} at 5 years, and 32{\%} at 7 years) was significantly longer (p <.01) than that of Child-Pugh B patients (50{\%} at 3 years, 28{\%} at 5 years, and 8{\%} at 7 years). A selected group of 70 patients with Child-Pugh A cirrhosis and a single lesion ≤ 3 cm had a 3-, 5-, and 7-year survival of 89{\%}, 63{\%} and 42{\%}, respectively. During the follow-up, new lesions appeared in 93 patients. The recurrence rates by the Kaplan-Meier method were 15{\%} at 1 year, 34{\%} at 2 years, 51{\%} at 3 years, 67{\%} at 4 years, 78{\%} at 5 years, 88{\%} at 6 years, and 94{\%} at 7 years. The analysis of the survival curves of the treated patients confirms the effectiveness of PEI in the treatment of HCC. This therapeutic approach is particularly indicated for patients with a single lesion 3 cm or less in greatest diameter, as in these cases the long-term results of PEI are comparable to those reported in the best surgical series published in the literature.",
keywords = "HCC, interventional radiology, HCC, therapy, Liver neoplasms, therapy",
author = "Riccardo Lencioni and Alessandro Paolicchi and Carlo Bartolozzi",
year = "1997",
month = "7",
language = "Italian",
volume = "94",
pages = "8--13",
journal = "Radiologia Medica",
issn = "0033-8362",
publisher = "Springer-Verlag Italia",
number = "1-2",

}

TY - JOUR

T1 - Alcoolizzazione percutanea dell'epatocarcinoma

T2 - Risultati a lungo termine

AU - Lencioni, Riccardo

AU - Paolicchi, Alessandro

AU - Bartolozzi, Carlo

PY - 1997/7

Y1 - 1997/7

N2 - We investigated the long-term outcome of percutaneous ethanol injection (PEI) in the treatment of hepatocellular carcinoma (HCC). A series of 184 HCC patients received PEI as the sole anticancer treatment over an 8-year period, December, 1987, to December, 1995. Ninety-four patients had a single tumor ≤ 3 cm, 50 patients had a single lesion of 3.1-5 cm, and 40 patients had multiple nodules (up to four) ≤ 3 cm each. All patients had liver cirrhosis, classified as Child-Pugh class A in 127 cases and as Child-Pugh class B in 57 cases. The treatment schedule included, for each lesion, 6-14 therapeutic sessions performed once or twice weekly. The total amount of alcohol administered ranged 10 to 110 ml (mean: 36 ml). All patients were followed after therapy with clinical examinations, laboratory tests, and imaging studies performed at regular time intervals. The follow-up period ranged 2 to 94 months (mean: 23.6 months). Overall survival rates by the Kaplan-Meier method were 67% at 3 years, 41% at 5 years, and 19% at 7 years. The survival rates of patients with single lesion ≤3 cm (78% at 3 years, 54% at 5 years, and 28% at 7 years, respectively) were significantly higher (p <.01) than those of the patients with a single lesion of 3.1-5 cm (61% at 3 years, 32% at 5 years, and 16% at 7 years) or multiple lesions (51% at 3 years, 21% at 5 years, and 0% at 7 years). The survival of Child-Pugh A patients (79% at 3 years, 53% at 5 years, and 32% at 7 years) was significantly longer (p <.01) than that of Child-Pugh B patients (50% at 3 years, 28% at 5 years, and 8% at 7 years). A selected group of 70 patients with Child-Pugh A cirrhosis and a single lesion ≤ 3 cm had a 3-, 5-, and 7-year survival of 89%, 63% and 42%, respectively. During the follow-up, new lesions appeared in 93 patients. The recurrence rates by the Kaplan-Meier method were 15% at 1 year, 34% at 2 years, 51% at 3 years, 67% at 4 years, 78% at 5 years, 88% at 6 years, and 94% at 7 years. The analysis of the survival curves of the treated patients confirms the effectiveness of PEI in the treatment of HCC. This therapeutic approach is particularly indicated for patients with a single lesion 3 cm or less in greatest diameter, as in these cases the long-term results of PEI are comparable to those reported in the best surgical series published in the literature.

AB - We investigated the long-term outcome of percutaneous ethanol injection (PEI) in the treatment of hepatocellular carcinoma (HCC). A series of 184 HCC patients received PEI as the sole anticancer treatment over an 8-year period, December, 1987, to December, 1995. Ninety-four patients had a single tumor ≤ 3 cm, 50 patients had a single lesion of 3.1-5 cm, and 40 patients had multiple nodules (up to four) ≤ 3 cm each. All patients had liver cirrhosis, classified as Child-Pugh class A in 127 cases and as Child-Pugh class B in 57 cases. The treatment schedule included, for each lesion, 6-14 therapeutic sessions performed once or twice weekly. The total amount of alcohol administered ranged 10 to 110 ml (mean: 36 ml). All patients were followed after therapy with clinical examinations, laboratory tests, and imaging studies performed at regular time intervals. The follow-up period ranged 2 to 94 months (mean: 23.6 months). Overall survival rates by the Kaplan-Meier method were 67% at 3 years, 41% at 5 years, and 19% at 7 years. The survival rates of patients with single lesion ≤3 cm (78% at 3 years, 54% at 5 years, and 28% at 7 years, respectively) were significantly higher (p <.01) than those of the patients with a single lesion of 3.1-5 cm (61% at 3 years, 32% at 5 years, and 16% at 7 years) or multiple lesions (51% at 3 years, 21% at 5 years, and 0% at 7 years). The survival of Child-Pugh A patients (79% at 3 years, 53% at 5 years, and 32% at 7 years) was significantly longer (p <.01) than that of Child-Pugh B patients (50% at 3 years, 28% at 5 years, and 8% at 7 years). A selected group of 70 patients with Child-Pugh A cirrhosis and a single lesion ≤ 3 cm had a 3-, 5-, and 7-year survival of 89%, 63% and 42%, respectively. During the follow-up, new lesions appeared in 93 patients. The recurrence rates by the Kaplan-Meier method were 15% at 1 year, 34% at 2 years, 51% at 3 years, 67% at 4 years, 78% at 5 years, 88% at 6 years, and 94% at 7 years. The analysis of the survival curves of the treated patients confirms the effectiveness of PEI in the treatment of HCC. This therapeutic approach is particularly indicated for patients with a single lesion 3 cm or less in greatest diameter, as in these cases the long-term results of PEI are comparable to those reported in the best surgical series published in the literature.

KW - HCC, interventional radiology

KW - HCC, therapy

KW - Liver neoplasms, therapy

UR - http://www.scopus.com/inward/record.url?scp=0030735685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030735685&partnerID=8YFLogxK

M3 - Article

C2 - 9424657

AN - SCOPUS:0030735685

VL - 94

SP - 8

EP - 13

JO - Radiologia Medica

JF - Radiologia Medica

SN - 0033-8362

IS - 1-2

ER -